Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis

NCT01823185 is registered in ClinicalTrials.gov with Imam Abdulrahman Bin Faisal University as lead sponsor.

NCT NCT01823185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01823185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis
Lead sponsor
Imam Abdulrahman Bin Faisal University
Phase
Phase 4
Overall status
Unknown status
Start date
March 31, 2013
Completion date
March 31, 2016
Enrollment
1,500 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

angina pectoris, cardiovascular disease, chest pain, coronary artery disease, embolism, heart disease, infarction, ischemia, myocardial infarction, thrombosis, vascular disease